Is Hepatology a Good Journal? The AASLD Liver Flagship
Hepatology is the AASLD flagship with IF 15.8, the premier US liver journal. Here's when your paper fits, what editors want, and how it compares to J. Hepatology, Gut, and Lancet Gastroenterology.
Research Scientist, Neuroscience & Cell Biology
Author context
Works across neuroscience and cell biology, with direct expertise in preparing manuscripts for PNAS, Nature Neuroscience, Neuron, eLife, and Nature Communications.
Journal fit
See whether this paper looks realistic for Hepatology.
Run the Free Readiness Scan with Hepatology as your target journal and see whether this paper looks like a realistic submission.
Hepatology at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 15.8 puts Hepatology in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~15% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: Hepatology takes ~30 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
How to read Hepatology as a target
This page should help you decide whether Hepatology belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | Hepatology is THE liver journal. If you study any aspect of liver biology or disease, this is your target. |
Editors prioritize | Liver-specific expertise and insight |
Think twice if | Generic inflammation studies applied to liver |
Typical article types | Original Research, Brief Communication, Clinical Research |
Quick answer: Hepatology (IF 15.8, JCR 2024) is the AASLD flagship and the premier US liver journal. It is a strong journal for clinical and translational hepatology with complete, field-level evidence. It is a weak journal for liver-adjacent studies that lack specificity or for incremental observations from small cohorts.
The Editorial Distinction
Hepatology is THE US liver journal. Published by the American Association for the Study of Liver Diseases, it shapes how American hepatologists practice. AASLD guidelines reference its published evidence, and the journal's readership is the audience that implements those guidelines.
The editorial question is: is this paper important enough to change how hepatologists understand or treat liver disease?
"Important enough" means the paper has to do more than document a liver-related finding. It has to feel complete, definitive, and relevant across the hepatology community. A well-powered clinical trial on NAFLD treatment belongs here. A pilot biomarker study on 40 patients from one center does not, even if the biomarker is interesting.
The Numbers
Metric | Value |
|---|---|
Impact Factor (JCR 2024) | 15.8 |
5-Year IF | ~14.2 |
Publisher | Wiley (for AASLD) |
Quartile | Q1 in Gastroenterology and Hepatology |
Acceptance rate | ~15-20% |
APC | Free (subscription) with OA option |
Scope | Clinical, translational, and basic liver disease research |
How Hepatology Compares
Journal | IF (2024) | Acceptance | Best For |
|---|---|---|---|
Hepatology | 15.8 | ~15-20% | Clinical/translational hepatology, AASLD community |
Journal of Hepatology | 33.0 | ~10-15% | Liver disease, EASL community, highest-IF liver journal |
Gut | 25.8 | ~8% | Broad GI and hepatology, BMJ |
Lancet Gastroenterology & Hepatology | 38.6 | ~5-8% | High-impact clinical GI/liver, Lancet family |
Liver International | 5.2 | ~25-30% | Solid liver research below Hepatology bar |
Hepatology vs Journal of Hepatology: This is the central comparison for liver researchers. J. Hepatology (IF 25.5, EASL) has nearly double the IF and is currently the most impactful dedicated liver journal globally. The gap has widened in recent years. For the strongest liver papers, J. Hepatology is often the first attempt. Hepatology remains the AASLD home journal, and US-based hepatologists publish there naturally, but the IF gap is real and increasingly visible in career evaluations.
Hepatology vs Gut: Gut (IF 25.8) covers all of GI medicine and hepatology. Its higher IF and broader readership make it attractive for liver papers with general GI relevance. If the paper is exclusively liver-focused, Hepatology provides the more targeted audience. If it speaks to GI physicians broadly, Gut is the stronger venue.
Hepatology vs Lancet Gastroenterology & Hepatology: Lancet Gastro (IF 24.8) is the most selective option, publishing major clinical trials and practice-changing evidence. It's the target for the very best clinical liver studies. Hepatology is the tier below for clinical work and the natural home for translational and mechanistic hepatology that Lancet wouldn't publish.
Hepatology vs Liver International: Liver International (IF 6.0) is the realistic alternative when a paper is solid but doesn't reach Hepatology's bar. It's less selective and provides a good venue for well-done liver research that lacks the scope or sample size for a flagship journal.
Submit If
- The paper makes a definitive point about liver disease that changes understanding or practice
- The evidence package is complete: adequate sample size, external validation where needed, clear clinical or mechanistic significance
- The natural readership is the US hepatology community (AASLD-aligned)
- The study is liver-specific, not liver-adjacent work from a GI or metabolic context
Journal fit
See whether this paper looks realistic for Hepatology.
Run the scan with Hepatology as the target. Get a manuscript-specific fit signal before you commit.
Think Twice If
- The paper is strong enough for J. Hepatology or Gut, try there first, as the IF gap is substantial
- The study is a small, single-center observation without clear generalizability
- The liver framing is secondary to a broader metabolic, GI, or immunological story
- Liver International or a specialty journal would give the paper a more engaged readership at a realistic acceptance probability
- You're choosing Hepatology for the AASLD brand rather than because the paper genuinely merits flagship-level attention
What we see before submission
In our pre-submission review work with manuscripts targeting Hepatology, the most consistent desk-rejection pattern is still liver-adjacent framing without liver-specific proof. Papers often use hepatocytes, liver tissue, or liver biomarkers as the experimental context, but the real mechanism is still generic inflammation, metabolism, or fibrosis signaling that could have been told in many organs.
The second repeat problem is cell-line-heavy evidence without primary or in vivo liver validation. For hepatology claims, immortalized hepatocyte data is usually a starting point, not the finish line. The journal's audience expects a paper to say something dependable about liver biology, liver disease, or hepatology practice.
The third problem is descriptive biomarker work without mechanistic or clinical consequence. A marker association can be interesting, but if the manuscript does not explain why the marker changes, whether it improves liver-disease decision-making, or how it connects to hepatic pathogenesis, the paper usually reads as incomplete for a flagship liver journal.
Frequently Asked Questions
Has Hepatology lost ground to Journal of Hepatology?
In terms of IF, yes. J. Hepatology (IF 25.5) has significantly outpaced Hepatology (IF 15.8) over the past decade. This reflects EASL's growing influence and J. Hepatology's editorial strategy. Hepatology remains a top-tier liver journal, but authors should be aware that the journals are no longer equivalent in impact metrics.
What about Hepatology Communications?
Hepatology Communications is the AASLD's companion open-access journal (IF ~5.5). It's positioned as an alternative when Hepatology is too selective. Some papers are transferred from Hepatology to Hepatology Communications after rejection. It's a legitimate OA venue within the AASLD family.
Does Hepatology publish basic science?
Yes, but with a requirement for liver relevance. Basic liver biology (fibrosis mechanisms, hepatocyte biology, liver regeneration) fits if the biological insight matters to the hepatology community. Pure molecular biology without clear liver disease relevance belongs in a molecular biology journal.
How long does review take?
First decisions typically come within 4-8 weeks. Desk rejections arrive faster, usually within 1-2 weeks. The journal handles substantial submission volume, and turnaround times have been stable.
Before submitting, a Hepatology scope and readiness check can help you assess whether your liver paper is positioned for Hepatology or better matched to J. Hepatology, Gut, or Liver International.
Before you submit
A Hepatology submission readiness check identifies the specific framing and scope issues that trigger desk rejection before you submit.
Why timing your submission matters
Journal editorial capacity fluctuates. Submissions during major conference seasons face longer reviewer turnaround. End-of-year submissions may sit longer during holiday periods. New IF announcements (June each year) can temporarily increase submissions to journals whose IF rose.
For selective journals, the practical advice is: submit when the manuscript is ready, not when the calendar seems favorable. A paper that is scientifically complete and properly targeted will succeed regardless of timing. A paper with gaps will fail regardless of when you submit.
A Hepatology submission readiness check evaluates fit independently of timing.
How to use this information strategically
A Hepatology scope and readiness check gives you the verdict: does your paper fit this journal?
Frequently asked questions
Hepatology has a 2024 JCR impact factor of 15.8, ranked Q1 in Gastroenterology and Hepatology. It is the official journal of the American Association for the Study of Liver Diseases (AASLD) and the premier US-based liver journal.
Journal of Hepatology, the EASL flagship, currently carries a higher JIF than Hepatology. Hepatology is the AASLD counterpart and remains a major US liver journal. The choice often depends on audience fit: AASLD-connected work and US cohorts lean toward Hepatology, while EASL-aligned work and European cohorts often lean toward Journal of Hepatology.
The most common desk rejections are for papers that are liver-adjacent but not liver-specific enough, small single-center studies without external validation, and descriptive biomarker studies without mechanistic depth or clinical utility. The journal wants complete, field-level liver science, not incremental observations.
Gut has a higher JIF and broader GI scope. For a liver paper that also speaks to broader GI medicine, Gut can be the stronger choice. For a liver-specific paper whose natural readership is hepatologists, Hepatology is the more targeted venue. Gut is also more selective than Hepatology.
Sources
- Hepatology journal homepage, Wiley / AASLD.
- Hepatology author guidelines, Wiley / AASLD.
- Clarivate Journal Citation Reports (JCR 2024, released June 2025).
Final step
See whether this paper fits Hepatology.
Run the Free Readiness Scan with Hepatology as your target journal and get a manuscript-specific fit signal before you commit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
Compare alternatives
Supporting reads
Conversion step
See whether this paper fits Hepatology.
Anthropic Privacy Partner. Zero-retention manuscript processing.